Lundbeck and Otsuka have begun collaborating on development of a preclinical Alzheimer's disease vaccine candidate. The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year. Lundbeck is financing the trial and has received $5.5 million from Otsuka. Once Phase I data is in, the partners will decide whether to establish an alliance for the rest of development and commercialization. Release